| 25 Janvier 2018
The burden of chronic kidney disease (CKD) in the seven major markets (7MM*) is expected to grow at a Compound Annual Growth Rate of 9.9% between 2016 and 2026, according to GlobalData, a leading data and analytics company.
CKD, also known as chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time. As the disease progresses, the symptoms worsen, eventually leading to kidney failure.
Qaisrah Khalid, Healthcare Analyst at GlobalData, comments: “In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of CKD, stages I–V, will grow by 9.9% over the forecast period, at an Annual Growth Rate (AGR) of 0.99%, from just under 25.78 million cases in 2016 to just under 28.33 million cases in 2026.”
In 2016, the US accounted for 21.56% of the diagnosed prevalent cases of CKD in the 7MM, with just under 5.56 million cases. There were almost 17.19 million cases in the 5EU, with 66.68% of the diagnosed prevalent cases. Japan had approximately 3.03 million cases, accounting for 11.77% of the diagnosed prevalent cases in the 7MM in 2016. Of the 7MM, the UK is expected to have the highest number of diagnosed prevalent cases, increasing from 13,397,021 in 2016 to 14,035,651 in 2026. GlobalData’s epidemiology analysis found that the UK has a much higher rate of diagnosis for stages 1 and 2 of CKD than any of the other markets.
* 7MM = US, 5EU (France, Germany, Italy, Spain, UK), and Japan
